Xencor Inc
XNCR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XNCR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XNCR
Xencor Inc is a clinical-stage biopharmaceutical company that engineers bispecific antibodies and Fc technologies to develop biologic medicines for severe and life-threatening diseases, with a pipeline spanning oncology and autoimmune indications.
Key risk: Clinical-stage pipeline risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.94B
Cash Runway
10.2 moLead Asset
AIMab7195 (XmAb7195) (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 9 pipeline candidates · 12 clinical trials · 1 catalyst for Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company that engineers bispecific antibodies and Fc technologies to develop biologic medicines for severe and life-threatening diseases, with a pipeline spanning oncology and autoimmune indications.
- Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered biologic medicines for severe and life-threatening diseases with unmet medical needs [sec_mda · as of 2026-08-05].
- As of 2026-06-30, the company reported cash & equivalents of $44.9M, total revenue of $51.2M, net income of -$21.7M, shareholders' equity of $635.6M, and total debt of $104.9M [sec].
- Xencor's pipeline includes XmAb942 (anti-TL1A with extended half-life) in a global Phase 2b XENITH-UC study for ulcerative colitis, with first-in-human data showing favorable tolerability and a 12-week maintenance dosing interval [sec · filed 2026-04-27].
- The company advanced XmAb412 as its lead TL1A x IL-23p19 bispecific antibody and plans to initiate first-in-human studies in the second half of 2026 [sec · filed 2026-04-27].
- Xencor paused development of vudalimab and XmAb564/XmAb662 cytokine candidates to prioritize resources for other pipeline programs [sec · filed 2025-04-23].
What works
- Xencor's XmAb platform enables the engineering of bispecific antibodies and Fc domains, which can be leveraged through partnerships and collaborations to generate revenue streams and expand the pipeline [sec · filed 2024-04-24].
- The company has multiple clinical-stage programs in autoimmune diseases (e.g., XmAb942, plamotamab) and oncology, with plans to advance toward pivotal studies in 2027 [sec · filed 2026-04-27].
- Xencor reported a strong shareholders' equity of $635.6M as of 2026-06-30, indicating a solid capital base to support ongoing R&D activities [sec].
What to weigh
- Xencor is a clinical-stage company with no approved products, and its pipeline programs are in early phases of clinical development, reflecting a pre-commercial status [sec · filed 2025-04-23].
- The company reported a net loss of $21.7M for the period ending 2026-06-30, highlighting ongoing operating losses typical of development-stage biotech firms [sec].
- Xencor has paused or discontinued several programs (vudalimab, XmAb564, XmAb662), indicating pipeline attrition and resource reallocation risks [sec · filed 2025-04-23].
- Cash & equivalents of $44.9M as of 2026-06-30 may be relatively low compared to the company's operating needs, though total debt of $104.9M provides additional leverage [sec].
From the filings
Quoted directly from source documents.
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered biologic medicines.
“We are a clinical-stage biopharmaceutical company focused on discovering and developing”
SEC MD&A · August 5, 2026
XmAb942 demonstrated favorable tolerability and an extended half-life supporting a 12-week maintenance dosing interval.
“we presented first-in-human data for XmAb942, demonstrating favorable tolerability and an extended half-life supporting a 12-week maintenance dosing interval”
SEC filings · April 27, 2026
Xencor paused development of vudalimab and XmAb564/XmAb662.
“We paused further development of vudalimab and have prioritized resources to advance other pipeline programs. • We concluded Phase 1 studies evaluating our XmAb564 and XmAb662 cytokine drug candidates and paused further development of both programs.”
SEC filings · April 23, 2025
Xencor plans to initiate first-in-human studies for XmAb412 in the second half of 2026.
“We also advanced XmAb412 as our lead TL1A x IL-23p19 bispecific antibody and plan to initiate first-in-human studies in the second half of 2026.”
SEC filings · April 27, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · xmab942 — Phase 2 Readout: xmab942 — Topline data from the Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis will be a key efficacy and safety readout for the program.
Risks & what to watch (4)›
Key risks
- Clinical-stage pipeline risk — All programs are in early clinical development with no approved products, leading to high uncertainty and potential failure [sec · filed 2025-04-23].
- Operating losses and cash burn — Net loss of $21.7M in latest period and cash of $44.9M may require future financing to sustain operations [sec].
- Pipeline attrition — Multiple programs (vudalimab, XmAb564, XmAb662) have been paused or discontinued, reducing pipeline breadth [sec · filed 2025-04-23].
- Regulatory and competitive risk — XmAb942 and other candidates face competition from other TL1A and bispecific antibodies in development [sec · filed 2026-04-27].
What to watch
- Phase 2b XENITH-UC study topline data for XmAb942 in ulcerative colitis, expected in the second half of 2026 [sec · filed 2026-04-27].
- Initiation of first-in-human studies for XmAb412 (TL1A x IL-23p19) in the second half of 2026 [sec · filed 2026-04-27].
- Additional clinical data from plamotamab in rheumatoid arthritis and XmAb657 in idiopathic inflammatory myopathies [sec · filed 2026-04-27].
- Progress toward pivotal studies planned for 2027 in oncology and autoimmune programs [sec · filed 2026-04-27].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Xencor Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xencor Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.2 months
D/E 0.44 · 0% dilution
Lead: Approved
9 candidates
1 upcoming, next in ~123d
0 buys · 16 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
201
Total value held
$972.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,035,918 | $157.2M |
| primecap management co/ca/ | 10,338,022 | $124.7M |
| bvf inc/il | 7,133,720 | $86.0M |
| rtw investments, lp | 6,777,461 | $81.7M |
| vanguard capital management llc | 6,203,294 | $74.8M |
| ra capital management, l.p. | 4,897,237 | $59.1M |
| state street corp | 4,352,036 | $52.5M |
| vanguard portfolio management llc | 3,500,342 | $42.2M |
| geode capital management, llc | 1,815,577 | $21.9M |
| morgan stanley | 1,558,290 | $18.8M |
Showing top 10 of 201 institutional holders of Xencor Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 21.7%
- Days to cover
- 11.4
- Shares short
- 11,295,359
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XNCR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xencor Inc?
Xencor Inc is a clinical-stage biopharmaceutical company that engineers bispecific antibodies and Fc technologies to develop biologic medicines for severe and life-threatening diseases, with a pipeline spanning oncology and autoimmune indications.
What is Xencor Inc's lead drug candidate?
Xencor Inc's most advanced tracked candidate is AIMab7195 (XmAb7195) (Phase 1) for allergic indications (designed to reduce blood levels of IgE).
What is Xencor Inc's next catalyst?
Xencor Inc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: xmab942" — expected December 31, 2026.
Who is the CEO of Xencor Inc?
Dr. Bassil I. Dahiyat Ph.D. is the chief executive officer of Xencor Inc (XNCR).
Where is Xencor Inc headquartered?
Xencor Inc (XNCR) is headquartered in Pasadena, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.